Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Casodex · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Casodex | DRUG | 150mg once daily |
| Tamoxifen | DRUG | - |
Inclusion Criteria: * Subjects with adenocarcinoma of the prostate gland but with no evidence of distant metastasis. The stage of disease should be T1-T4, any N, M0 confirmed histologically or cytologically * Subjects in need of immediate hormonal therapy. * PSA equal or above 4 ng/ml Exclusion Cr...
Casodex is used for gynaecomastia, a condition of breast enlargement in males. It is being studied in the context of prostate cancer, as the clinical trial for this indication enrolled male patients with gynaecomastia and prostate cancer. The drug is a small molecule being developed by AstraZeneca.
Casodex is a small molecule that targets androgen receptors. By binding to these receptors, it blocks the effects of androgens, which are male hormones that can stimulate the growth of certain tissues. This mechanism is relevant to its use in gynaecomastia and prostate cancer.
Casodex is developed by AstraZeneca PLC, a biopharmaceutical company listed on the stock exchange under the ticker AZN. AstraZeneca is responsible for the clinical development of Casodex for the treatment of gynaecomastia.
Casodex is in Phase 2 clinical development for gynaecomastia. It is an investigational drug and has not been approved for this indication. The Phase 2 trial has been completed, and the drug is no longer in active clinical testing for this condition.
Casodex has been studied in one clinical trial with the identifier NCT00637871, titled "Casodex - Nolvadex Combination." This Phase 2 trial was a randomized, double-blind, active-controlled study that has been completed. The trial enrolled male patients with gynaecomastia and prostate cancer.
No, Casodex is not the same as Nolvadex. Casodex is a small molecule that targets androgen receptors, while Nolvadex is a different drug. In the clinical trial NCT00637871, Casodex was studied in combination with Nolvadex, indicating they are distinct medications used together in the study.